default author photo

Nizar M. Tannir

University of Texas at Houston - Department of Genitourinary Medical Oncology

1901 East Road, Unit 1950

Houston, TX 77030

United States

SCHOLARLY PAPERS

4

DOWNLOADS

414

TOTAL CITATIONS

0

Scholarly Papers (4)

1.

Efficacy of Pembrolizumab in Patients with Advanced Rare Cancers

Number of pages: 41 Posted: 31 May 2019
University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, Baylor College of Medicine, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston, Health Science Center at Houston (UTHealth), MD Anderson Cancer Center, Department of Radiology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Thoracic/Head and Neck Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas Rio Grande Valley (UTRGV) (Formerly University of Texas-Pan American), University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, University of Texas at Houston - Investigational Cancer Therapeutics, R Simon Consulting, University of Texas at Houston - Department of Biostatistics, University of Texas at Houston - MD Anderson Cancer Center and University of Texas at Houston - MD Anderson Cancer Center
Downloads 152 (488,442)

Abstract:

Loading...

2.

Pegilodecakin Combined with Anti-PD-1 Monoclonal Antibodies for Patients with Advanced Renal Cell Carcinoma (IVY): A Multicentre, Open-Label, Phase 1b Trial

Number of pages: 35 Posted: 05 Mar 2019
University of Texas at Houston - Investigational Cancer Therapeutics, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, University of California, Los Angeles (UCLA), University of California, San Francisco (UCSF), University of Texas at Houston - MD Anderson Cancer Center, START Center for Cancer Care, Memorial Sloan Kettering Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, University of California, Los Angeles (UCLA), University of Texas at Houston - Department of Leukemia, ARMO BioSciences, ARMO BioSciences, ARMO BioSciences, ARMO BioSciences, ARMO BioSciences, Eli Lilly and Company, Ltd - Eli Lilly and Company, NYC, ARMO BioSciences and University of Texas at Houston - Department of Genitourinary Medical Oncology
Downloads 148 (500,001)

Abstract:

Loading...

Renal cancer, Pegilodecakin, Nivolumab, Pembrolizumab, phase 1, IL-10, pegylated IL-10

3.

Phase II Trial Investigating Definitive Radiation Therapy in Lieu of Systemic Therapy for Oligometastatic Renal Cell Carcinoma

Number of pages: 22 Posted: 02 Aug 2021
University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston, Health Science Center at Houston (UTHealth), MD Anderson Cancer Center, Department of Radiology, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Radiation Oncology, University of Texas at Houston - Department of Radiation Physics, University of Texas at Houston - Department of Radiation Physics, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Interventional Radiology, University of Texas at Houston - Department of Translational Molecular Pathology and University of Texas at Houston - Department of Genitourinary Medical Oncology
Downloads 63 (933,592)

Abstract:

Loading...

4.

Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma

Number of pages: 86 Posted: 19 Sep 2019
University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Strasbourg - Department of Hematology and Oncology, University of Texas at Houston - Department of Bioinformatics and Computational Biology, University of Texas at Houston - Department of Bioinformatics and Computational Biology, Baylor University - Center for Precision Environmental Health, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Pathology, Baylor University - Department of Molecular and Cellular Biology, University of Texas at Houston - Department of Bioinformatics and Computational Biology, University of Texas at Houston - Department of Genetics, University of Texas at Houston - Department of Immunology, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Genitourinary Medical Oncology, University of Texas at Houston - Department of Genitourinary Medical Oncology, Baylor college of Medicine - Center for Precision Environmental Health, Baylor college of Medicine - Center for Precision Environmental Health, Baylor University - Department of Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Institute for Applied Cancer Science, University of Texas at Houston - Institute for Applied Cancer Science, University of Texas at Houston - Institute for Applied Cancer Science, University of Texas at Houston - Department of Immunology, University of Texas at Houston - Department of Urology, University of Texas at Houston - Department of Urology, Baylor college of Medicine - Center for Precision Environmental Health, University of Texas at Houston - Department of Genitourinary Medical Oncology and University of Texas at Houston - Department of Genitourinary Medical Oncology
Downloads 51 (1,063,489)

Abstract:

Loading...

Molecular profiling, renal medullary carcinoma, replication stress, SMARCB1, cGAS-STING pathway